CDK4/6抑制剂在激素受体阳性乳腺癌治疗中的应用  

Application of CDK4/6 inhibitors in the treatment of hormone receptor-positive breast cancer

作　　者：莫秋萍 陈益定[1] 王晓晨[1,2] Mo Qiuping;Chen Yiding;Wang Xiaochen(Department of Breast Surgery,Second Affiliated Hospital,Zhejiang University School of Medicine,Hangzhou 310009,China;Department of Breast Surgery,Zhejiang Provincial People′s Hospital,Hangzhou 310014,China)

机构地区：[1]浙江大学医学院附属第二医院乳腺外科,杭州310009 [2]浙江省人民医院乳腺外科,杭州310014

出　　处：《国际肿瘤学杂志》2019年第10期617-619,共3页Journal of International Oncology

基　　金：浙江省自然科学基金(LY19H160056)。

摘　　要：细胞周期依赖性蛋白激酶(CDK)4/6抑制剂因可阻滞细胞增殖,成为激素受体阳性乳腺癌有效且安全的治疗选择。CDK4/6抑制剂联合内分泌治疗方案能显著改善激素受体阳性晚期乳腺癌患者的预后,尤其可改善内分泌耐药患者预后。CDK4/6抑制剂的适应证还有望拓宽到早期乳腺癌中。但CDK4/6抑制剂耐药机制仍不明确。With roles of blocking cell proliferation,cyclin-dependent protein kinase(CDK)4/6 inhi-bitors are effective and safe complementary therapies for hormone receptor-positive breast cancer.CDK4/6 inhibitors combined with endocrine therapy significantly improve the prognosis of patients with advanced or metastatic breast cancer,especially those with endocrine resistance.Indications for CDK4/6 inhibitors are also expected to broaden into early-stage breast cancer.However,mechanisms of resistance of CDK4/6 inhibitors remain elusive.

关 键 词：乳腺肿瘤 受体 雌激素 细胞周期蛋白质依赖激酶类 治疗学 

分 类 号：R73[医药卫生—肿瘤]